Published in Science on June 01, 2007
lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res (2010) 4.49
Mitochondria in innate immune responses. Nat Rev Immunol (2011) 3.31
Decoding human cytomegalovirus. Science (2012) 2.98
Mitochondrial disorders as windows into an ancient organelle. Nature (2012) 2.51
Viral control of mitochondrial apoptosis. PLoS Pathog (2008) 2.21
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
Retracted GRIM-19-mediated translocation of STAT3 to mitochondria is necessary for TNF-induced necroptosis. J Cell Sci (2012) 2.05
Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell (2008) 2.04
Is HCMV a tumor promoter? Virus Res (2010) 1.81
Concern The functional role of long non-coding RNAs and epigenetics. Biol Proced Online (2014) 1.73
MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One (2009) 1.67
High-resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci U S A (2011) 1.67
On the classification of long non-coding RNAs. RNA Biol (2013) 1.53
Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev (2008) 1.50
The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia (2009) 1.49
Antisense transcription in the human cytomegalovirus transcriptome. J Virol (2007) 1.40
Discrete clusters of virus-encoded micrornas are associated with complementary strands of the genome and the 7.2-kilobase stable intron in murine cytomegalovirus. J Virol (2007) 1.39
Human cytomegalovirus protein pUL38 induces ATF4 expression, inhibits persistent JNK phosphorylation, and suppresses endoplasmic reticulum stress-induced cell death. J Virol (2009) 1.38
West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. J Virol (2012) 1.35
Constitutive ERK MAPK activity regulates macrophage ATP production and mitochondrial integrity. J Immunol (2008) 1.30
Viral modulation of programmed necrosis. Curr Opin Virol (2013) 1.20
Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA. PLoS Pathog (2010) 1.16
Cross-regulation between herpesviruses and the TNF superfamily members. Nat Rev Immunol (2008) 1.15
Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus. Mol Cell Proteomics (2010) 1.14
Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathog (2013) 1.12
GRIM-19 is essential for maintenance of mitochondrial membrane potential. Mol Biol Cell (2008) 1.10
Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem (2009) 1.08
Genomic and functional characteristics of human cytomegalovirus revealed by next-generation sequencing. Viruses (2014) 1.05
Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci U S A (2011) 1.03
Quantitative proteomic analyses of human cytomegalovirus-induced restructuring of endoplasmic reticulum-mitochondrial contacts at late times of infection. Mol Cell Proteomics (2011) 1.02
Genomic analysis of codon, sequence and structural conservation with selective biochemical-structure mapping reveals highly conserved and dynamic structures in rotavirus RNAs with potential cis-acting functions. Nucleic Acids Res (2010) 1.02
BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection. Proc Natl Acad Sci U S A (2012) 1.01
PNPASE and RNA trafficking into mitochondria. Biochim Biophys Acta (2011) 1.01
HtrA2/Omi terminates cytomegalovirus infection and is controlled by the viral mitochondrial inhibitor of apoptosis (vMIA). PLoS Pathog (2008) 1.00
Viral noncoding RNAs: more surprises. Genes Dev (2015) 0.99
Long non-coding RNAs (lncRNAs) and viral infections. Biomed Pharmacother (2013) 0.98
Eukaryotic complex I: functional diversity and experimental systems to unravel the assembly process. Mol Genet Genomics (2008) 0.97
The human cytomegalovirus protein UL37 exon 1 associates with internal lipid rafts. J Virol (2010) 0.96
Murine cytomegalovirus m38.5 protein inhibits Bax-mediated cell death. J Virol (2008) 0.92
Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus. Med Microbiol Immunol (2012) 0.90
Increased resistance of complex I mutants to phytosphingosine-induced programmed cell death. J Biol Chem (2008) 0.88
Cytokine-induced tumor suppressors: a GRIM story. Cytokine (2010) 0.88
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection. Curr HIV/AIDS Rep (2016) 0.87
Immunology. Outwitted by viral RNAs. Science (2007) 0.86
Rotenone enhances the antifungal properties of staurosporine. Eukaryot Cell (2010) 0.86
Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res (2009) 0.86
Human Cytomegalovirus Latency: Approaching the Gordian Knot. Annu Rev Virol (2016) 0.86
Noncoding RNPs of viral origin. Cold Spring Harb Perspect Biol (2011) 0.86
Prevention of cellular suicide by cytomegaloviruses. Viruses (2012) 0.84
Current knowledge of MicroRNAs and noncoding RNAs in virus-infected cells. Methods Mol Biol (2010) 0.84
GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression. J Biol Chem (2010) 0.84
Genomics and the immune system. Immunology (2008) 0.84
The role of long non-coding RNAs in genome formatting and expression. Front Genet (2015) 0.83
TNFR1/phox interaction and TNFR1 mitochondrial translocation Thwart silica-induced pulmonary fibrosis. J Immunol (2014) 0.82
On the relative roles of background selection and genetic hitchhiking in shaping human cytomegalovirus genetic diversity. Mol Ecol (2015) 0.82
Human cytomegalovirus inhibits apoptosis by proteasome-mediated degradation of Bax at endoplasmic reticulum-mitochondrion contacts. J Virol (2013) 0.82
Long Non-Coding RNAs in Infection Biology. Front Genet (2013) 0.81
Human cytomegalovirus manipulation of latently infected cells. Viruses (2013) 0.81
Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activity. Am J Pathol (2010) 0.81
Multiplicity-dependent activation of a serine protease-dependent cytomegalovirus-associated programmed cell death pathway. Virology (2012) 0.80
The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases. Aging Dis (2016) 0.79
Epigenetics and Genetics of Viral Latency. Cell Host Microbe (2016) 0.79
Viral product trafficking to mitochondria, mechanisms and roles in pathogenesis. Infect Disord Drug Targets (2012) 0.79
Functional annotation of human cytomegalovirus gene products: an update. Front Microbiol (2014) 0.79
Whole transcriptome sequencing enables discovery and analysis of viruses in archived primary central nervous system lymphomas. PLoS One (2013) 0.78
Regulation of the subcellular distribution of key cellular RNA-processing factors during permissive human cytomegalovirus infection. J Gen Virol (2010) 0.78
Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev Med Virol (2015) 0.78
Diverse mechanisms evolved by DNA viruses to inhibit early host defenses. Crit Rev Biochem Mol Biol (2016) 0.78
Long noncoding RNAs in viral infections. Virus Res (2015) 0.78
Viral mitochondria-localized inhibitor of apoptosis (UL37 exon 1 protein) does not protect human neural precursor cells from human cytomegalovirus-induced cell death. J Gen Virol (2012) 0.77
Landscape of post-transcriptional gene regulation during hepatitis C virus infection. Curr Opin Virol (2015) 0.77
Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries. MBio (2016) 0.76
GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses. Transl Oncogenomics (2008) 0.76
Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro. J Gen Virol (2014) 0.76
Divergent viral presentation among human tumors and adjacent normal tissues. Sci Rep (2016) 0.75
GRIM-19 Restricts HCV Replication by Attenuating Intracellular Lipid Accumulation. Front Microbiol (2017) 0.75
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism. Cytokine Growth Factor Rev (2016) 0.75
lncRNA-mediated regulation of the interferon response. Virus Res (2015) 0.75
HCMV activation of ERK-MAPK drives a multi-factorial response promoting the survival of infected myeloid progenitors. J Mol Biochem (2017) 0.75
Human Cytomegalovirus Delays Neutrophil Apoptosis and Stimulates the Release of a Prosurvival Secretome. Front Immunol (2017) 0.75
Die Another Day: Inhibition of Cell Death Pathways by Cytomegalovirus. Viruses (2017) 0.75
Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. Int J Oncol (2017) 0.75
Genetic content of wild-type human cytomegalovirus. J Gen Virol (2004) 3.58
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J (2002) 2.06
Modulation of natural killer cells by human cytomegalovirus. J Clin Virol (2008) 1.90
Two novel spliced genes in human cytomegalovirus. J Gen Virol (2003) 1.87
Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol (2005) 1.86
Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. J Biol Chem (2006) 1.64
Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 1.60
Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol (2010) 1.51
Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest (2010) 1.50
Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques (2008) 1.33
Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J Gen Virol (2009) 1.31
The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J Immunol (2007) 1.29
Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science (2013) 1.27
The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO J (2006) 1.22
The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. J Immunol (2010) 1.16
Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modification. J Gen Virol (2009) 1.11
Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation. J Virol (2008) 1.08
Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proc Natl Acad Sci U S A (2012) 1.07
Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18. J Immunol (2012) 1.04
Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses. J Virol (2013) 0.98
The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? Cell Mol Immunol (2014) 0.95
Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J Virol (2013) 0.91
Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. J Gen Virol (2005) 0.91
Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. J Gen Virol (2004) 0.90
Knockdown of hDaxx in normally non-permissive undifferentiated cells does not permit human cytomegalovirus immediate-early gene expression. J Gen Virol (2007) 0.90
Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proc Natl Acad Sci U S A (2013) 0.89
Adenovirus vector delivery stimulates natural killer cell recognition. J Gen Virol (2007) 0.86
The use of primary human cells (fibroblasts, monocytes, and others) to assess human cytomegalovirus function. Methods Mol Biol (2014) 0.86
Differential relocation and stability of PML-body components during productive human cytomegalovirus infection: detailed characterization by live-cell imaging. Eur J Cell Biol (2010) 0.82
Human cytomegalovirus modulation of CCR5 expression on myeloid cells affects susceptibility to human immunodeficiency virus type 1 infection. J Gen Virol (2006) 0.82
Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter. J Gen Virol (2009) 0.81